| abstract |
The invention relates to the use of reverse transcriptase (RT) inhibitor compounds for the preparation of pharmaceutical compositions for counteracting the loss of cell differentiation in cancer and non-cancer pathologies, these compounds being able to bind to the hydrophobic pocket of the p66 RT subunit. The following compounds are particularly preferred for such use: nevirapine, efavirenz, delavirdine, their corresponding salts and / or pharmaceutically acceptable derivatives. |